Nebenwirkungen · Rinvoq
RINVOQ 15 mg prolonged-release tablets RINVOQ 30 mg prolonged-release tablets RINVOQ 45 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 20
HOS-141650 · Präparat HOS-098682
In the placebo-controlled induction studies, the frequency of infection over 8 weeks in the upadacitinib 45 mg group compared to the placebo group was 20.7% and 17.5%, respectively. In the placebo-controlled maintenance study, the frequency of infection over 52 weeks in the upadacitinib 15 mg and 30 mg groups was 40.4% and 44.2%, respectively, compared to 38.8% in the placebo group. The long-term rate of infections for upadacitinib 15 mg and 30 mg was 64.5 and 77.8 events per 100 patient-years, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T09:40:00Z · SHA-256 5de239efd759454fb94dd5492aaf011cbc6b7e353af434d7085ca61eb8be1f59 · Passage df15e29d445ac20b4609fac18ca9336c26fddf631dd9b8195affd0eac194ccd0 · Zeichen 17112–17625 im Abschnitt